scholarly journals Clinicopathological Characteristics and Survival Outcomes of Patients with Buccal Squamous Cell Carcinoma: Results of a Multi-Institutional Study

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1361
Author(s):  
Shogo Shinohara ◽  
Masahiro Kikuchi ◽  
Hiroyuki Harada ◽  
Kiyomi Hamaguchi ◽  
Ryo Asato ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Postoperative Radiotherapy ◽  
Stage Iv ◽  
Clinicopathological Characteristics ◽  
Survival Outcome ◽  
Primary Site ◽  
Survival Outcomes ◽  
Cancer Stage ◽  
Oral Cancers ◽  
Buccal Squamous Cell Carcinoma

Background and Objectives: To investigate clinicopathological characteristics and survival outcomes of patients with buccal cancer in Japan. Materials and Methods: This study was conducted using a database of 1055 patients with oral cancers treated between 2010 and 2017 at 12 institutions in Japan. Ninety-two patients (8.7%) with primary buccal cancer were extracted and clinicopathological characteristics and survival outcomes were compared between patients with buccal cancers and patients with other oral cancers. Results: Ages were significantly higher in the patients with buccal cancer (73 years old vs. 69 years old). Buccal cancer had less advanced cT stage and cN stage than other oral cancers. Overall 5-year survival (OS) was 80.6%, and recurrence-free 5-year survival (RFS) of buccal cancers was 67.8%, and there were no significant differences in survival compared with other oral cancers in terms OS or RFS (5y-OS: 82.5%, 5y-RFS: 74.4%). However, patients with stage IV buccal cancer showed poorer prognosis in terms of OS and RFS compared with the same stage patients with other oral cancer. Advanced T stage was the only factor independently associated with both OS and RFS of patients with buccal cancer in this study. Conclusions: Postoperative radiotherapy or chemoradiotherapy should be considered to improve survival outcome of buccal cancer patients, especially for the patients with advanced primary site disease or a higher cancer stage.

scholarly journals Evaluation of 2 Commercially Systems for Detection of Serum Squamous Cell Carcinoma Antigen in Pan Squamous Cell Carcinoma

2020 ◽  
Vol 27 (1) ◽  
pp. 107327482098302
Author(s):  
Hao Chen ◽  
Liru Tian ◽  
Jiahong Chen ◽  
Peng Sun ◽  
Runkun Han ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Stage Iv ◽  
Cervical Squamous Cell Carcinoma ◽  
Stage I ◽  
Cancer Stage ◽  
Squamous Cell Carcinoma Antigen

Background: This study compared the analytical performance of the Elecsys 602 (Roche Diagnostics) system with the I2000 (Abbott laboratories) system for the quantitative measurement of squamous cell carcinoma antigen (SCCA) to assess its role as an indicator in pan squamous cell carcinoma. Methods: 435 serum samples included pan squamous cell cancer group (n = 318) and healthy subjects (n = 52) and non-squamous cell group (n = 41) and benign diseases group (n = 24) were measured by 2 systems and compared. Results: The within-run precision coefficient of variation (CV) for Abbott and Roche systems were 3.34-4.88% and 0.95 -1.96%, and the total precision CV were 2.89-9.48% and 3.97-5.38%, respectively. Good correlation was showed in Abbott and Roche systems (slopes = 0.749, r = 0.9658). Serum SCCA in the groups of nasopharyngeal carcinomas, lung squamous cell carcinoma, esophageal squamous cell carcinoma, bladder cancer and cervical squamous cell carcinoma under the curve area (AUC) was more than 0.5, while the AUC in the non- nasopharyngeal carcinomas head and neck squamous cell carcinoma was less than 0.5. The AUC of 2 systems was statistically different in lung squamous cell carcinoma and nasopharyngeal carcinomas (P < 0.05). The levels of SCCA of 2 systems were similarities in esophageal squamous cell carcinoma(stage IV vs. stage 0a-II)and bladder cancer(stage I vs. stage Oa)and cervical squamous cell carcinoma(stage IIB-III vs. stage I-IIA), which advanced stage had higher level of SCCA than early stage. But the SCCA levels of 2 systems were inconsistent in bladder cancer (stage II-IV vs. stage Oa in Abbott), head and neck squamous cell carcinoma (stage IV vs. stage Oa-I in the Roche) and lung squamous cell carcinoma (stage III vs. stage I-II in the Roche). (P < 0.05) Conclusions: 2 systems correlated well in SCCA detection of squamous cell carcinoma, but there were individual differences. Serum SCCA may also contribute to the diagnosis of bladder cancer.

Effect of clinical stage on survival outcome in patients with pathological stage I gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 178-178
Author(s):  
Masanori Tokunaga ◽  
Rie Makuuchi ◽  
Yuichiro Miki ◽  
Yutaka Tanizawa ◽  
Etsuro Bando ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Stage ◽  
Clinicopathological Characteristics ◽  
Survival Outcome ◽  
Nodal Status ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Pathological Stage ◽  
Gastric Cancer Patients

178 Background: Patients with clinical stage (cStage) II or III gastric cancer are possible candidates for neoadjuvant chemotherapy. In this situation, contamination of pathological stage (pStage) I patients, for whom gastrectomy without adjuvant chemotherapy is a standard treatment of care, is a problem. However, it is unclear whether survival outcome in patients with cStage II-III / pStage I gastric cancer is as good as that of patients with cStage I / pStage I disease. The aim of the present study is to clarify the effect of clinical stage on survival outcome in patients with pStage I gastric cancer. Methods: The present study included 558 patients with pStage I gastric cancer who underwent gastrectomy between 2002 and 2006 at Shizuoka Cancer Center, Japan. Clinicopathological characteristics were investigated, and survival outcome was compared between cStage I and cStage II-III. In addition, we investigated the effect of other clinical factors, including clinically diagnosed tumor depth (cT) and nodal status (cN), on survival outcome. Results: The present retrospective cohort includs 368 male and 190 female patients, with median age of 64 years Five-year survival rate (5ysr) was significantly worse in cStage II-III (84.2%) than in cStage I (95.5%, p=0.003). 5ysr was also worse in cT2-4 (86.6%) than in cT1 (96.3%, p<0.001). On the contrary, clinical nodal status did not affect survival outcome of pStage I patients. Conclusions: cT and cStage affected survival outcomes of patients with pStage I gastric cancer. Patients who are preoperatively diagnosed with advanced disease have worse survival outcomes and can be candidates for neoadjuvant chemotherapy.

scholarly journals Outcomes in Squamous Cell Carcinoma with Advanced Neck Disease

2007 ◽  
Vol 89 (7) ◽  
pp. 703-708 ◽  
Author(s):  
James A Keir ◽  
Olivia JH Whiteside ◽  
Stuart C Winter ◽  
Sushir Maitra ◽  
Rogan C Corbridge ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Postoperative Radiotherapy ◽  
Stage Iv ◽  
Surgical Excision ◽  
Kaplan Meier ◽  
Neck Disease ◽  
Stage Iv Disease

INTRODUCTION Treatment of advanced neck disease (N2c/N3) in head and neck squamous cell carcinoma is contentious. The aim of this study was to review the survival outcome following surgical excision of neck disease and the complications of this surgery. PATIENTS AND METHODS A retrospective review of the case notes of 39 patients treated at the Oxford Radcliffe Infirmary Head and Neck Unit with squamous cell carcinoma and advanced neck metastases confirmed as either pN2c or pN3 on histological examination was performed. Patients were treated with surgery and, in some cases, with adjunctive postoperative radiotherapy at the centre between August 1996 and November 2004. The study sought to establish the demographics, UICC staging/pathology, method of treatment, complications, recurrence and survival. Kaplan-Meier curves were used for statistical analysis of survival. Comparisons were then made between the cohort and historical control groups. RESULTS All patients were UICC stage IV disease. The 2- and 5-year overall survival in patients with resectable disease was 63% and 52%, respectively. DISCUSSION Patients with advanced neck disease have traditionally been thought to have terrible prognosis and, therefore, treatment is controversial. In treating advanced head and neck cancer, there has been a recent trend away from surgery towards chemotherapy and/or radiotherapy. CONCLUSIONS Comparing this study group to historical controls that include chemotherapy and/or radiotherapy, the outcomes appear favourable. The use of a combination of radiotherapy and surgery is advocated; it is suggested that advanced neck disease can have an acceptable prognosis and morbidity and that local disease control may be achieved.

scholarly journals Survival effect of postoperative radiotherapy combined with lymph nodes examined on cavity squamous cell carcinoma patients with stage T1-2N1M0: a propensity‑adjusted SEER database analysis

2021 ◽  
Author(s):  
Wen-Mei Jiang ◽  
Zhong-Yi Fang ◽  
Yu-Dong Li ◽  
Huan-Ye Wei ◽  
An-Kui Yang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Postoperative Radiotherapy ◽  
Survival Outcome ◽  
Cancer Specific Survival ◽  
Group A ◽  
Multivariable Analyses ◽  
Survival Effect

Abstract Background To explore the association between postoperative radiotherapy (PORT) combined with lymph nodes examined (LNE) and the survival outcome for pT1-2N1M0 oral cavity squamous cell carcinoma (OCSCC) patients. Methods This study retrieved patients who underwent dissection of primary site and neck lymph nodes for pT1-2N1 OCSCC without adverse nodal features from the Surveillance, Epidemiology, and End Results database from 2004 to 2015. Patients were divided into groups according if PORT was conducted. Propensity score matching (PSM) analysis was conducted and the best cut-off value of the LNE was determined by X-tile. Cancer-specific survival (CSS) was the primary outcome. Univariable and multivariable analyses were performed to assess the relation between PORT and CSS, adjusting for other prognostic factors. Results A total of 469 patients were finally enrolled according to our exclusion criteria and then 170 pairs of patients were matched by PSM. The best cut-off value of the LNE was determined by X-tile, stratifying patients into LNE ≤ 16 group and LNE > 16 group. For the whole matched cohort, whether patients chose PORT had no correlation with other factors (all p > 0.05), and it revealed that PORT made no contribution to a better survival outcome for patients (p = 0.253). While stratified by the LNE, among the LNE ≤ 16 group, a statistically significant improved CSS was found for those who undertook PORT (hazard ratio, 0.521; 95% confidence interval, 0.294–0.925; p = 0.022). Conclusions The PORT made no contribution on CSS of OCSCC patients with pT1-2N1M0 stage on the whole cohort. While among the LNE ≤ 16 group, PORT conferred a superior CSS compared with surgery only, indicating the necessity for surgeons to conduct a thorough neck dissection.

scholarly journals Predictors of outcome in pleomorphic xanthoastrocytoma

2020 ◽  
Author(s):  
Antonio Dono ◽  
Victor Lopez-Rivera ◽  
Ankush Chandra ◽  
Cole T Lewis ◽  
Rania Abdelkhaleq ◽  
...  
Keyword(s):  
Tumor Size ◽  
Postoperative Radiotherapy ◽  
Treatment Strategies ◽  
Pleomorphic Xanthoastrocytoma ◽  
Survival Outcomes ◽  
Factors Affecting ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
Cox Proportional Hazard Models ◽  
Male Patients

Abstract Background Pleomorphic xanthoastrocytomas (PXA) are circumscribed gliomas that typically have a favorable prognosis. Limited studies have revealed factors affecting survival outcomes in PXA. Here, we analyzed the largest PXA dataset in the literature and identify factors associated with outcomes. Methods Using the Surveillance, Epidemiology, and End Results (SEER) 18 Registries database, we identified histologically confirmed PXA patients between 1994 and 2016. Overall survival (OS) was analyzed using Kaplan-Meier survival and multivariable Cox proportional hazard models. Results In total, 470 patients were diagnosed with PXA (males = 53%; median age = 23 years [14-39 years]), the majority were Caucasian (n = 367; 78%). The estimated mean OS was 193 months [95% CI: 179-206]. Multivariate analysis revealed that greater age at diagnosis (≥39 years) (3.78 [2.16-6.59], P &lt; .0001), larger tumor size (≥30 mm) (1.97 [1.05-3.71], P = .034), and postoperative radiotherapy (RT) (2.20 [1.31-3.69], P = .003) were independent predictors of poor OS. Pediatric PXA patients had improved survival outcomes compared to their adult counterparts, in which chemotherapy (CT) was associated with worse OS. Meanwhile, in adults, females and patients with temporal lobe tumors had an improved survival; conversely, tumor size ≥30 mm and postoperative RT were associated with poor OS. Conclusions In PXA, older age and larger tumor size at diagnosis are risk factors for poor OS, while pediatric patients have remarkably improved survival. Postoperative RT and CT appear to be ineffective treatment strategies while achieving GTR confer an improved survival in male patients and remains the cornerstone of treatment. These findings can help optimize PXA treatment while minimizing side effects. However, further studies of PXAs with molecular characterization are needed.

266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A292-A292
Author(s):  
Sophie Wildsmith ◽  
Jill Walker ◽  
Anne L’Hernault ◽  
Weimin Li ◽  
Hannah Bye ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Phase Iii ◽  
Survival Outcomes ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Unresectable Stage ◽  
First Line Treatment

BackgroundThe phase III DANUBE study assessed the efficacy of the PD-L1 inhibitor durvalumab (D), alone or in combination with the CTLA-4 inhibitor tremelimumab (T), versus standard of care chemotherapy (SoC) for the first-line treatment of unresectable, locally advanced or metastatic UC. The study did not meet its co-primary endpoints of improving overall survival (OS) for D monotherapy vs SoC in patients with high tumor PD-L1 expression or for D+T vs SoC in the intention-to-treat population.1 TMB measurement in blood (bTMB) or tumour (tTMB) has been linked to improved efficacy with PD-1/PD-L1 inhibitors in UC and with D+T in non-small cell lung cancer,2 thus providing a rationale to explore TMB in the DANUBE trial.MethodsBaseline plasma samples from DANUBE were assessed for bTMB using the Guardant OMNI platform, while baseline tTMB was measured in formalin-fixed paraffin-embedded (FFPE) tumour samples using the FoundationOne CDx gene panel. Associations between progression-free survival (PFS) and median and landmark OS with bTMB and tTMB levels at various cutoffs were assessed as part of a pre-specified exploratory analysis. The data cutoff occurred on January 27, 2020.ResultsAmong 1032 patients randomised in DANUBE, 536 (51.9%) were evaluable for bTMB and 623 (60.4%) were evaluable for tTMB. For D vs SoC, bTMB and tTMB were not associated with OS or PFS at any cutoff. For D+T, stronger associations between bTMB and OS as well as PFS were observed with increasing bTMB cutoffs (table 1). At the bTMB cutoff ≥ 24 mut/Mb, 12-month OS rates were 76.7% for D+T and 54.3% for SoC, whereas for bTMB < 24 mut/Mb, 12-month OS rates were 53.4% for D+T and 51.2% for SoC. Similar trends for both OS and PFS were observed with tTMB (table 1).Abstract 266 Table 1Association between TMB and survival outcomes with D+TAssociation between TMB and survival outcomes with D+TConclusionsBoth bTMB and tTMB are potentially useful biomarkers for enriching responses to D+T in previously untreated, advanced UC. Neither bTMB nor tTMB was associated with better outcomes for D monotherapy. Cutoffs of 24 mut/Mb for bTMB and 10 mut/Mb for tTMB appear optimal for D+T in the setting of previously untreated, advanced UC.Trial RegistrationThe trial is registered with ClinicalTrials.gov, NCT02516241, and the EU Clinical Trials Register, EudraCT number 2015-001633-24.ReferencesAstraZeneca. Update on phase III DANUBE trial for IMFINZI and tremelimumab in unresectable, stage IV bladder cancer [press release] March 6, 2020. [https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html]Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020:6:661–674.Ethics ApprovalThe study protocol was approved by the Ethics Board at each investigator’s institution.

Sign in / Sign up

Export Citation Format

Share Document